John H. Rex, MD
Chief Medical Officer, F2G Ltd. · Operating Partner, Advent Life Sciences · Adjunct Professor of Medicine, McGovern Medical School
I am a physician and drug developer with more than 40 years of development and policy experience focused on antimicrobial agents. My experience includes moving antifungal and antibacterial agents from preclinical development thru all development phases in the context of (a) academic positions (NIAID, University of Texas-Houston), (b) VP-level roles at a pharmaceutical multinational (AstraZeneca), (c) board-level roles in in biotech companies (F2G, Ltd.; Adenium Biotech ApS), (d) serving as Expert-in-Residence at Wellcome Trust, (e) Chief Strategy Officer for CARB-X, (f) an Operating Partner role with Advent Life Sciences, and Chair of the Scientific Advisory board of the $1b AMR Action Fund. The first 15 years of my career were as an academic physician focused on medical mycology and my work spanned susceptibility testing methods, in vitro-in vivo translational studies, and clinical trials. After moving to Industry in 2003, my work has broadened to include advancing novel regulatory and reimbursement paradigms for antimicrobial agents, founding of the New Drugs for Bad Bugs (ND4BB) program of Europe’s Innovative Medicines Initiative (IMI), and support of cross-Industry initiatives to encourage development of novel antimicrobials. I currently work primarily as the Chief Medical Officer for F2G, Limited, a privately owned biotech company working on development of new antifungal agents.